First study to evaluate alternative to warfarin for mechanical heart valve patients launched with Pradaxa® (dabigatran etexilate)
20 June 2012 | By Boehringer Ingelheim
The design of the RE-ALIGN study published...
List view / Grid view
News
Merck statement on CDC Advisory Committee on Immunization Practices’ recommendation for pneumococcal vaccination
20 June 2012 | By Merck
Merck provided the following statement...
AstraZeneca completes acquisition of Ardea Biosciences
20 June 2012 | By AstraZeneca
AstraZeneca has completed its acquisition of San Diego, California-based biotechnology company Ardea Biosciences, Inc...
Pfizer statement regarding Prevnar 13® receiving ACIP recommendation for prevention of pneumococcal disease
20 June 2012 | By Pfizer
Pfizer issued the following statement...
Roche and Seaside Therapeutics announce landmark alliance to advance novel treatments for FXS and ASD
19 June 2012 | By Roche
Roche and Seaside Therapeutics have entered into a collaboration...
Positive results from Phase 3 study PROFILE 1007 evaluating XALKORI® (crizotinib) in previously treated patients with ALK-Positive advanced NSCLC
19 June 2012 | By Pfizer
Detailed study results to be presented...
Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
19 June 2012 | By Sanofi
Sanofi and the Joslin Diabetes Center announced a new collaboration...
Geisinger & Merck to collaborate on multi-year effort to improve patient adherence, engagement & care delivery
18 June 2012 | By Merck
Geisinger & Merck enter a new multi-year collaboration...
EMA validates Gilead’s marketing application for Elvitegravir for treatment of HIV infection
18 June 2012 | By Gilead Sciences
Gilead Sciences announced that its MAA for elvitegravir has been validated by the EMA...
FDA issues complete response letter for Pfizer’s tafamidis meglumine New Drug Application
18 June 2012 | By Pfizer
Tafamidis is a novel, investigational medication for the treatment of TTR-FAP...
Boehringer Ingelheim BioXcellence
18 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim BioXcellence: Distinctive brand for the biopharmaceutical contract manufacturing business...
Abbott presents results of clinical studies evaluating its investigational treatment for advanced Parkinson’s disease
18 June 2012 | By Abbott
Results from five abstracts announced...
AF patients who require surgery benefit from a shorter treatment interruption on dabigatran etexilate (Pradaxa®) compared to warfarin
18 June 2012 | By Boehringer Ingelheim
Pradaxa® is associated with a substantially shorter interruption of oral anticoagulation therapy...
USON promotes 18-year company leader to Global Sales Director
18 June 2012 | By ALM Communications Inc.
Dave Foran, President of USON, is pleased to announce the appointment of Gene Grilli to be USON Global Sales Director...
USON announces appointment of Charles D. Foran Jr. as company President
18 June 2012 | By ALM Communications Inc.
USON, announces the appointment of an award-winning veteran of the automated instrumentation industry, Charles D. Foran Jr. (Dave), as USON President...
